Журнал эпилепсии

Epilepsy is a complex neurological disorder characterized by recurrent, unprovoked seizures. Affecting approximately 1 in 26 people over their lifetime, its management and treatment have historically been challenging, particularly due to the heterogeneous nature of the condition. Its underlying causes are multifaceted, but genetic factors play a pivotal role in many cases. Understanding the genetic basis of epilepsy has been transformative, shedding light on its pathophysiology and leading to more personalized treatment approaches. However, recent advances in genetics have provided profound insights into the molecular underpinnings of epilepsy, leading to the identification of key genetic mutations that have significant implications for treatment and personalized medicine.

Epilepsy, a chronic neurological disorder characterized by recurrent seizures, affects approximately 50 million people worldwide. While traditional antiepileptic drugs have made significant strides in managing this condition, there is an ongoing need for novel treatments that offer improved efficacy, fewer side effects and enhanced quality of life for patients. Recent advancements in drug development have led to the emergence of several new AEDs, which have been evaluated in recent clinical trials. Antiepileptic drugs are pivotal in managing epilepsy, a neurological disorder marked by recurrent seizures. Despite the efficacy of established AEDs, the search for new drugs continues due to limitations like insufficient efficacy in refractory cases, adverse side effects and individual variability in drug responses. The advent of novel AEDs reflects advances in our understanding of epilepsy's pathophysiology and pharmacology, aiming to offer improved outcomes.

Epilepsy, a neurological disorder characterized by recurrent seizures, affects approximately 50 million people worldwide. Historically, the management of epilepsy has relied on a one-size-fits-all approach, with antiepileptic drugs (AEDs) prescribed based on general seizure type and broad patient characteristics. However, recent advancements in personalized medicine are revolutionizing this paradigm by tailoring treatments to individual genotypes, offering the promise of more effective and precise management for patients. Antiepileptic Drugs (AEDs), also known as anticonvulsants, are medications used to manage and prevent seizures in individuals with epilepsy. Epilepsy is a neurological disorder characterized by recurrent seizures, which can vary widely in type and severity. AEDs aim to control these seizures, improve the quality of life and reduce the frequency and intensity of epileptic episodes.

Epilepsy, a neurological disorder characterized by recurrent seizures, affects millions of people worldwide. While its primary symptoms are related to seizure activity, epilepsy is frequently accompanied by a range of psychiatric disorders. Understanding the intricate relationship between epilepsy and comorbid psychiatric conditions is essential for effective treatment and improved quality of life for patients. While the primary focus of epilepsy management often revolves around controlling seizures, it is crucial to recognize that many individuals with epilepsy also experience psychiatric disorders. These comorbid psychiatric conditions can significantly impact the patient's overall well-being and complicate epilepsy management. The relationship between epilepsy and psychiatric disorders is bidirectional, meaning that individuals with epilepsy are at an increased risk of developing psychiatric conditions and conversely, psychiatric disorders can influence the course and management of epilepsy. Common psychiatric comorbidities include anxiety disorders, depression and psychosis.